November 21, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced that the Company completed its adoption of International Financial Reporting Standards ("IFRS") accounting standards with the filing of amended financial statements for the three months ended March 31, 2011 and the three and six months ended June 30, 2011. The adoption of IFRS had no effect on the financial results previously reported by the Company.

November 21, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced financial and operational results for the three and nine months ended September 30, 2011.

October 18th, 2011 - Medwell Capital Corp. ("Medwell") today announced that it has made a further $880,000 investment in Mimetogen Phamaceuticals Inc. ("Mimetogen"). This investment is the final tranche of the $2 Million funding by Medwell announced on February 25, 2011.

October 3, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced that the Company will present its financial statements in accordance with International Financial Reporting Standards ("IFRS").

TORONTO, Ontario and EDMONTON, Alberta - September 9, 2011 - Spectral Diagnostics Inc. ("Spectral") (TSX: SDI) and Medwell Capital Corp. ("Medwell") (TSX-V: MWC) today announced that they have completed their previously announced plan of arrangement (the "Arrangement"), pursuant to which Medwell acquired a further 33,333,333 Spectral common shares (the "Spectral Shares") for $10 million, at a subscription price of $0.30 per share, the gross proceeds of which will be used primarily to advance Spectral's Toraymyxin, a treatment for severe sepsis, through to the end of its U.S. Phase III EUPHRATES trial and data release. Pursuant to the Arrangement, Medwell also distributed 54,282,834 Spectral Shares to its shareholders, representing approximately $16.3 million in value based on the $0.30 Spectral Share subscription price.